1
|
|
2
|
Hilger RA, Richly H, Grubert M, Libicher M, Strumberg D, Ebert J, Hecker D, Zähringer M. Pharmacokinetics of intra-arterial applied liposomal encapsulated doxorubicin in liver metastases or hepatocellular carcinoma: A phase I study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.13523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006; 17:866-73. [PMID: 16500908 DOI: 10.1093/annonc/mdl017] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Sorafenib (BAY 43-9006), a novel, oral multi-kinase inhibitor, blocks serine/threonine and receptor tyrosine kinases in the tumor and vasculature. Sorafenib demonstrated single-agent activity in Phase I studies, and was tolerated and inhibited tumor growth in combination with doxorubicin in preclinical studies. This Phase I dose-escalation study determined the safety, pharmacokinetics and efficacy of sorafenib plus doxorubicin. PATIENTS AND METHODS Thirty-four patients with refractory, solid tumors received doxorubicin 60 mg/m(2) on Day 1 of 3-week cycles, and oral sorafenib from Day 4 of Cycle 1 at 100, 200 or 400 mg bid. RESULTS Common drug-related adverse events were neutropenia (56%), hand-foot skin reaction (44%), stomatitis (32%), and diarrhea (32%). The maximum tolerated dose was not reached. One patient with pleural mesothelioma achieved a partial response (modified WHO criteria) and remained on therapy for 39.7 weeks. Fifteen patients (48%) achieved stable disease for >/=12 weeks. Doxorubicin exposure increased moderately with sorafenib 400 mg bid. The pharmacokinetics of sorafenib and doxorubicinol were not affected. CONCLUSION Sorafenib 400 mg bid plus doxorubicin 60 mg/m(2) was well tolerated. The increased doxorubicin exposure with sorafenib 400 mg bid did not result in significantly increased toxicity; low patient numbers make the clinical significance of this unclear. These promising efficacy results justify further clinical investigation.
Collapse
Affiliation(s)
- H Richly
- West German Cancer Center, University of Essen, Essen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Hilger RA, Richly H, Grubert M, Oberhoff C, Strumberg D, Scheulen ME, Seeber S. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx?/Doxil. Int J Clin Pharmacol Ther 2005; 43:588-9. [PMID: 16372528 DOI: 10.5414/cpp43588] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- R A Hilger
- Department of Internal Medicine (Cancer Research), University of Essen Medical School, West German Cancer Center, Essen, Germany.
| | | | | | | | | | | | | |
Collapse
|
5
|
Hilger RA, Richly H, Grubert M, Oberhoff C, Scheulen ME, Strumberg D, Seeber S. Pharmacokinetics (PK) of the liposomal encapsulated fraction as well as released doxorubicin after intravenous infusion of liposomal doxorubicin. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - H. Richly
- Univ of Essen Medcl Sch, Essen, Germany
| | | | | | | | | | - S. Seeber
- Univ of Essen Medcl Sch, Essen, Germany
| |
Collapse
|
6
|
Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Voigtmann R, Schwartz B, Brendel E, Christensen O, Haase CG, Strumberg D. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004; 42:650-1. [PMID: 15598035 DOI: 10.5414/cpp42650] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- H Richly
- West German Cancer Center, University of Essen, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Richly H, Kupsch P, Passarge K, Grubert M, Hilger RA, Haase CG, Schwartz B, Scheulen ME, Seeber S, Strumberg D. Results of a phase I trial of BAY 43–9006 in combination with doxorubicin in patients with refractory solid tumors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Richly
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - P. Kupsch
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - K. Passarge
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - M. Grubert
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - R. A. Hilger
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - C. G. Haase
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - B. Schwartz
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - M. E. Scheulen
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - S. Seeber
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| | - D. Strumberg
- University Medical School of Essen, Essen, Germany; Bayer AG, Clinical Pharmacology, Wuppertal, Germany; Bayer Corp., Westhaven, CT
| |
Collapse
|
8
|
Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Kredtke S, Voliotis D, Scheulen ME, Seeber S, Strumberg D. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther 2003; 41:620-1. [PMID: 14692720 DOI: 10.5414/cpp41620] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- H Richly
- University of Essen, West German Cancer Center, Essen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Müller HJ, Port RE, Grubert M, Hilger RA, Scheulen M, Mross K. The influence of liver metastases on the pharmacokinetics of doxorubicin a population-based pharmacokinetic project of the CESAR-APOH. Int J Clin Pharmacol Ther 2003; 41:598-9. [PMID: 14692710 DOI: 10.5414/cpp41598] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- H J Müller
- Department of Physiological Chemistry, University of Marburg, Germany.
| | | | | | | | | | | |
Collapse
|
10
|
Müller HJ, Grubert M, Hilger R, Richly H, Port R, Scheulen M, Mross K. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology. Int J Clin Pharmacol Ther 2002; 40:575-7. [PMID: 12503820 DOI: 10.5414/cpp40575] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- H J Müller
- Department of Physiological Chemistry, University of Marburg, Germany
| | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Rutishauser R, Grubert M. The architecture of Mourera fluviatilis (Podostemaceae): developmental morphology of inflorescences, flowers, and seedlings. Am J Bot 1999; 86:907-922. [PMID: 10406713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Mourera fluviatilis from northern South America is a spectacular member of the Podostemaceae (river-weeds). Its raceme-like inflorescences are up to 64 cm long and have 40-90 flowers arranged in two opposite rows. Inflorescence development starts with the initiation of a double-sheathed (dithecous) bract in a terminal position. All lateral bracts (again dithecous) are initiated in basipetal order along the two flanks of the inflorescence. Each gap between two neighboring bracts contains a single flower. The flowers are bisexual, each with a whorl of 16-20 ligulate tepals and 14-40 stamens, which are arranged in one or two whorls. Floral development starts with the formation of a girdling primordium rim around a two-lobed primordial gynoecium. Stamen and tepal initiation is centrifugal on the girdling primordium. The anthers are introrse or extrorse, depending on stamen position. Seedlings develop two entire, threadlike cotyledons, followed by forked filamentous leaves, which arise from the plumular pole. The radicular pole of the hypocotyl develops into a claw-shaped holdfast that fixes the young plant to the rock. The developmental morphologies of Mourera fluviatilis and other members of the Mourera group (including Lonchostephus and Tulasneantha) fit well with the Podostemoideae bauplan known from other New World genera, such as Apinagia and Marathrum.
Collapse
Affiliation(s)
- R Rutishauser
- Institut für Systematische Botanik der Universität Zürich, Zollikerstrasse 107, CH-8008 Zürich, Switzerland; and
| | | |
Collapse
|
13
|
Abstract
Investigation of the aerial parts of Rhyncholacis penicillata afforded the new chromenes, 7-hydroxy-6-(3-methylbutyryl)-5-oxymethyl-chromene (rhynchonin A) and 7-hydroxy-6-(2-methylbutyryl)-6-oxymethylchromene (rhynchonin B). Structures were elucidated by spectroscopic methods and independent synthesis. Rhynchonin A showed broad insecticidal, acaricidal and nematicidal potency including strong biological activity against Heliothis zea.
Collapse
Affiliation(s)
- G Burkhardt
- Universität des Saarlandes, Saarbrücken, Germany
| | | | | | | | | |
Collapse
|
14
|
Abstract
The heat effects involved in thermal unfolding of five tRNAs with different primary structures have been determined by direct differential scanning microcalorimetry. The overall molar values of the transition enthalpy (delta Ht) are 1150 kJ/mol for tRNA Lys2 (yeast), 1250 kJ/mol for tRNA Phe (yeast), 1350 kJ/mol for tRNA Val (yeast), 1490 kJ/mol for tRNA Val (E. coli) and 1630 kJ/mol for tRNA Tyr (E. coli). The tRNAs differ in their melting behaviour as can be shown by a comparison of the calorimetric curves. The calorimetrically measured delta Ht values are about 350 kJ/mol higher than the transition enthalpy values for the cloverleaf arrangement, which were estimated using the known parameters for G.C and A.U base pairs.
Collapse
|
15
|
Grubert M, Ackermann T. Ein empfindliches adiabatisches Diflerenzkalorimeter zur Untersuchung kooperativer Strukturumwandlungen in Lösungen. Z PHYS CHEM 1974. [DOI: 10.1524/zpch.1974.93.1-6.255] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Ackermann T, Bode D, Grubert M, Schernau U. Ein Beitrag zur Thermodynamik der Strukturumwandlung von Phenylalanin-spezifischer Transfer-Ribonucleinsäure in Lösung. Angew Chem Int Ed Engl 1974. [DOI: 10.1002/ange.19740861209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|